Insider buying last 90 days
No open-market insider purchases were filed for PSNL in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every PSNL insider filing, plotted on the chart in Gekko.Open PSNL in Gekko
NASDAQ: PSNL
Personalis (PSNL) Stock Analysis & Forecast
Oct 12 close
$15.80−0.20 (−1.2%)
Gekko Brief
Oct 12 closePersonalis closed at $15.80 on 12 October 2026, -1.2% on the day. The price sits between the 50-day ($15.87) and 200-day ($10.76) moving averages, inside a 52-week range of $4.96 to $18.89. The GekkoIndex reads 61.1, in the Accumulation zone, up 4.3 points over five sessions. Gekko Fair Value is $15.55, so the price is 1.6% above it.
The next earnings report is due on 3 November 2026, 22 days away (after close). Over the last 8 reports the company beat the earnings estimate 5 times, with an average move of 11.6% across the report. Seasonally, the next 20 trading days from this point averaged -6.5% over the last 5 years, rising in 2 of them.
5 firms rate the stock: 1 buy, 4 hold and 0 sell, with a consensus target of $15.17. A typical daily move is about 2.5%, and a typical 20-day move about 17.8%. On the swing-trade checklist, 1 item reads supportive and 2 read as a headwind (earnings risk, seasonality).
A plain summary of the figures as of the Oct 12, 2026 close.
Personalis price vs fair value
Close $15.80200-day averageGekko Fair Value $15.55
Personalis quick facts
- Market cap
- $1.69B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$1.09
- Revenue, TTM
- $69.67M
- Profit margin
- -153.8%
- Dividend yield
- —
- Beta
- 2.32
- Volume
- 2.25M avg 2.17M
- 1-year return
- +83.5%
- Typical daily move
- ±2.5%
- Typical 20-day move
- ±17.8%
- 50-day average
- $15.87
- 200-day average
- $10.76
- Next earnings
- Nov 3 after close
- Shares outstanding
- 106.8M
Personalis swing-trade checklist
Personalis scores 1 supportive, 2 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive2 mixed2 headwinds
- Trendmixed
Averages disagree
Close $15.80 sits between the 50-day ($15.87) and 200-day ($10.76) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
61.1, Accumulation
Reading 61.1 is in the Accumulation zone.
See the GekkoIndex - Fair valuemixed
1.6% above
Price is within 5% of Gekko Fair Value (1.6% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 22 days
Reports on Nov 3, 2026, 22 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−6.5% on average
From this point in the calendar, the next 20 trading days averaged −6.5% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Personalis stock chart and price history
Personalis closed at $15.80 on Oct 12, 2026, +83.5% over the past year, inside a 52-week range of $4.96 to $18.89.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −2.5%
- 3 months
- +5.1%
- 6 months
- +150.4%
- 1 year
- +83.5%
The full PSNL chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open PSNL in Gekko
Follow Personalis through every session
Put PSNL on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track PSNL in GekkoFree for 7 days. No credit card required.
About Personalis
Personalis focuses on genomics for cancer care, combining sequencing with data analysis to support the development of new cancer treatments and broader genetic research. Its main offering, the NeXT Platform, examines tumors and the immune tissue around them, working even with limited tissue or plasma samples. Within this platform sit several tools: ImmunoID Next for tissue-based tumor profiling, NeXT Liquid Biopsy and NeXT Personal for plasma-based and individual tumor tracking, the NeXT Dx Test for identifying treatment-guiding biomarkers, and NeXT SHERPA and NeXT NEOPS for neoantigen prediction. The company also provides the ACE platform, applied to tasks such as neoantigen prediction, biomarker discovery, and drug target selection.
Personalis works with biopharmaceutical companies, academic institutions, non-profit groups, and government bodies, and it has formed partnerships with organizations including Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center.
The company was founded in 2011 and is headquartered in Menlo Park, California. Its shares are listed on the NASDAQ under the ticker PSNL.
- Listed
- NASDAQ
- Sector
- Health services
- Industry
- Medical/Nursing services
- Website
- personalis.com
Personalis GekkoIndex: the smart money zone
Personalis’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 61.1, in the Accumulation zone, up 4.3 points over five sessions.
61.1Accumulation
Up 4.3 points over five sessions, from the Neutral zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 13 | +4.9% | +22.8% | ||
| Accumulation (current zone) | 262 | +2.8% | +19.6% | ||
| Neutral | 333 | +1.8% | +6.9% | ||
| Distribution | 70 | +6.6% | +8.7% | ||
| Selling | 4 | Too few readings yet | |||
Average PSNL share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the PSNL price, zone by zone.Track PSNL in Gekko
Is Personalis stock overvalued? Gekko Fair Value
Personalis trades 1.6% above Gekko Fair Value of $15.55, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Personalis shares are worth, recalculated every trading day.
$15.55
Gekko Fair Value, Oct 10, 2026
1.6% above fair value · About fair value
At the end of Aug 2026 the price was 12.2% above the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open PSNL in Gekko
Personalis insider and Congress trading
No open-market insider purchases were filed for Personalis, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in PSNL were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for PSNL, plotted on the chart in Gekko.Open PSNL in Gekko
Personalis earnings: next date and track record
Personalis reports on Nov 3, 2026, after the close (22 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 3, 2026
Expected after the close, 22 days away
- EPS estimate
- −$0.26
- Revenue estimate
- $21.54M
5 of 8reports beat the EPS estimate
±11.6%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | −$0.30 est −$0.26 | $22.36M est $16.69M | +2.4% |
| May 7, 2026 | −$0.29 est −$0.28 | $15.47M est $14.49M | −1.5% |
| Feb 26, 2026 | −$0.26 est −$0.28 | $17.35M est $17.05M | +9.0% |
| Nov 4, 2025 | −$0.24 est −$0.28 | $14.50M est $17.04M | −14.9% |
| Aug 5, 2025 | −$0.23 est −$0.25 | $17.20M est $20.12M | −20.8% |
| May 6, 2025 | −$0.18 est −$0.23 | $20.61M est $17.41M | +13.6% |
| Feb 27, 2025 | −$0.23 est −$0.32 | $16.80M est $15.48M | −7.6% |
| Nov 6, 2024 | −$0.64 est −$0.33 | $25.71M est $15.53M | −23.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Personalis stock forecast and analyst price targets
Analysts’ average 12-month price target for Personalis is $15.17, −4.0% from the last close, from 5 firms rating the stock in the last 90 days.
$15.17consensus 12-month target, −4.0% from the last close
Now $15.80Avg $15.17
Low $16.25High $18
Each firm’s latest rating in the last 90 days: 5 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 6 | BTIG | — | — |
| Aug 24 | Craig-Hallum | $16.25 | +2.8% |
| Aug 21 | Lake Street | $16.25 | +2.8% |
| Aug 6 | Needham | — | — |
| Aug 5 | Lake Street | $16.25 | +2.8% |
+19.6%average 20-day move after past Accumulation readings
−6.5%average move over the next 20 trading days in the last 5 years
±2.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Personalis seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Personalis averaged −6.5% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.4% | 2 of 5 |
| Next 10 trading days | −2.4% | 2 of 5 |
| Next 15 trading days | +1.2% | 3 of 5 |
| Next 20 trading days | −6.5% | 2 of 5 |
| Next 30 trading days | −6.7% | 2 of 5 |
For scale, PSNL’s typical 20-trading-day move in either direction is about 17.8%.
Personalis market cap and key statistics
Personalis’s market cap is $1.69B and revenue of $69.67M over the last twelve months.
Valuation
- Market cap
- $1.69B
- EPS, TTM
- −$1.09
- Gekko Fair Value
- $15.55
Trading
- Volume
- 2.25M
- Avg volume, 20 days
- 2.17M
- 52-week high
- $18.89
- 52-week low
- $4.96
- Shares outstanding
- 106.8M
Financials
- Revenue, TTM
- $69.67M
- Profit margin
- -153.8%
- Return on equity
- -50.3%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 2.32
- Typical daily move
- ±2.5%
- Typical 20-day move
- ±17.8%
Personalis stock news this week
Coverage of Personalis this week reads neutral: 2 positive, 1 neutral and 2 negative headlines.
- Personalis (PSNL) On Tempus Deal Optimism Looks Slightly PriceySimply Wall Street, Oct 8
- Tempus AI, Personalis saw US merger antitrust waiting period expireMLex, Oct 6
- A 30-day merger waiting period ends for Personalis (PSNL) and its proposed acquirer.Stock Titan, Oct 6
- Personalis downgraded at BTIG on likely Tempus takeoverTradingView, Oct 6
- BTIG downgrades Personalis stock rating to neutral on acquisition outlookInvesting.com, Oct 6
Personalis peers
Personalis’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Neutral | 2.5% below |
| GHGuardant Health | Accumulation | 10.0% below |
| SOLVSolventum | Accumulation | 20.5% below |
| BTSGBrightSpring Health Services | Neutral | 2.8% above |
| EHCEncompass Health | Neutral | 7.3% above |
| DVADaVita | Neutral | 14.6% below |
A peer links to its own page where one exists.
Personalis stock FAQ
What is Personalis’s market cap?
Personalis’s market cap is $1.69B at the Oct 12, 2026 close of $15.80, with 106.8M shares outstanding.
What is the Personalis stock forecast?
The consensus analyst 12-month price target for Personalis is $15.17, −4.0% from the last close. Of the 5 firms that rated the stock in the last 90 days, 1 rate it a buy, 4 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Personalis stock overvalued or undervalued?
On Gekko’s estimate Personalis is about fair value: the Oct 12, 2026 close of $15.80 is 1.6% above Gekko Fair Value of $15.55. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Personalis report earnings next?
Personalis is expected to report on Nov 3, 2026, after the market closes (22 days away). Analysts expect earnings of −$0.26 per share on revenue of $21.54M. Personalis beat the earnings estimate in 5 of its last 8 reports, moving 11.6% on average across the report.
What is Personalis’s 52-week high and low?
Personalis’s 52-week high is $18.89 and its 52-week low is $4.96; it closed at $15.80 on Oct 12, 2026, +83.5% over the past year. Over the last five years the shares peaked at $21.69 on Nov 5, 2021.
Is Personalis stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 5 items with data read as supportive (gekkoindex), 2 as mixed (trend and fair value) and 2 as headwinds (earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Personalis the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.